Clinical Trial Update: Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update reporting on the efficacy and safety of dendritic cytotoxic lymphocyte (DC-CTL) cell infusion in patients with non-small cell lung…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DC-CTL cell infusion (Dendritic Cytotoxic Lymphocyte (DC-CTL) cell infusion)

Snippet

Sponsor: Shenzhen Hornetcorn Bio-technology Company, LTD | Conditions: NSCLC | Phase 2 | Status: UNKNOWN